Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Based on an average trading volume of 286,800 shares, the days-to-cover ratio is presently 11.8 days. Currently, 7.4% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Monday. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $25.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Astria Therapeutics by 4.1% in the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 2,556 shares in the last quarter. Quest Partners LLC grew its position in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 8,965 shares during the last quarter. Wellington Management Group LLP increased its stake in Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 11,763 shares during the last quarter. Finally, PDT Partners LLC bought a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $140,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

NASDAQ:ATXS traded down $0.04 during mid-day trading on Thursday, hitting $7.75. 302,803 shares of the stock were exchanged, compared to its average volume of 336,190. The firm’s 50-day simple moving average is $9.60 and its 200 day simple moving average is $10.65. The stock has a market capitalization of $437.36 million, a price-to-earnings ratio of -3.71 and a beta of 0.70. Astria Therapeutics has a fifty-two week low of $6.95 and a fifty-two week high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.